ML390

Catalog No.S8382 Batch:S838201

Print

Technical Data

Formula

C21H21F3N2O3
Molecular Weight 406.4 CAS No. 2029049-79-2
Solubility (25°C)* In vitro DMSO 81 mg/mL (199.31 mM)
Ethanol 60 mg/mL (147.63 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ML390 is a human DHODH inhibitor with an IC50 of 0.56 μM and induces differentiation in acute myeloid leukemia.
Targets
DHODH [1]
(Cell-free assay)
0.56 μM
In vitro ML390 was active with an ED50 (effective concentration triggering 50% of its maximal differentiation activity) of 2 μM in murine and human AML cell lines, offering insight into the mechanism of overcoming differentiation arrest. DHODH inhibitors demonstrated effective at prolonging survival in animal models of leukemia[1].

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    Lys-GFP-ER-HoxA9 cells

  • Concentrations

    10 μM

  • Incubation Time

    48 h

  • Method

    Lys-GFP-ER-HoxA9 cells were treated in culture with 10 μM ML390 for 48 hr. The cells were washed three times in normal saline, and metabolites were extracted into 80% ice-cold methanol. Metabolites were analyzed. Negative ionization mode analyses of polar metabolites were acquired using an LC-MS system comprising an Acquity UPLC System (Waters) and a 5500 QTrap triple quadrupole mass spectrometer (AB SCIEX). Samples for negative ion mode analyses of polar metabolites were achieved using the HILIC (hydrophilic interaction chromatography) method under basic conditions as described previously, and MS data were acquired over m/z 70-750. MS data were processed using MultiQuant.

Selleck's ML390 has been cited by 2 publications

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus [ J Med Virol, 2024, 96(1):e29372] PubMed: 38235544
Identification of clinical candidates against West Nile Virus by activity screening in vitro and effect evaluation in vivo [ J Med Virol, 2022, 10.1002/jmv.27891] PubMed: 35644833

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.